Stockscreener 앱 받기
2.84
7.58%
0.20
시간 외 거래:
2.79
-0.05
-1.76%
전일 마감가:
$2.64
열려 있는:
$2.68
하루 거래량:
404.32K
Relative Volume:
1.76
시가총액:
$127.25M
수익:
$8,000
순이익/손실:
$-32.15M
주가수익비율:
-3.2794
EPS:
-0.866
순현금흐름:
$-26.37M
1주 성능:
+7.58%
1개월 성능:
+9.23%
6개월 성능:
-47.79%
1년 성능:
+15.45%
1일 변동 폭
$2.62
$2.86
1주일 범위
$2.30
$2.89
52주 변동 폭
$2.255
$8.535
Genelux Corp Stock (GNLX) Company Profile
명칭
Genelux Corp
전화
805-267-9889
주소
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.84 | 118.29M | 8,000 | -32.15M | -26.37M | -0.866 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Lake Street | Buy |
| 2024-10-29 | 개시 | Guggenheim | Buy |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-11-27 | 개시 | H.C. Wainwright | Buy |
| 2023-09-12 | 개시 | Maxim Group | Buy |
| 2023-02-15 | 개시 | The Benchmark Company | Speculative Buy |
모두보기
Genelux Corp 주식(GNLX)의 최신 뉴스
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis & Stock Price Forecast - Intellectia AI
Analyst Calls: Can Genelux Corporation outperform in the next rally2026 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn
GNLX PE Ratio & Valuation, Is GNLX Overvalued - Intellectia AI
Genelux head of regulatory sells $1.4k in shares By Investing.com - Investing.com Australia
Yu Yong, Genelux SVP, sells $2192 in GNLX stock By Investing.com - in.investing.com
Genelux CEO Zindrick sells $8668 in shares By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $1.4k in shares - investing.com
Cappello, Genelux CTO, sells $2192 in GNLX stock By Investing.com - Investing.com South Africa
Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com
Genelux CEO Zindrick sells $8668 in shares - Investing.com
Genelux (GNLX) Head of Regulatory sells 585 shares to cover RSU taxes - Stock Titan
[Form 4] GENELUX Corp Insider Trading Activity - Stock Titan
Genelux (NASDAQ: GNLX) SVP sells 906 shares to cover RSU taxes - Stock Titan
Genelux (GNLX) CEO sells shares to cover RSU tax obligations - Stock Titan
AI Stocks: Is Genelux Corporation showing insider buyingShort Setup & Technical Pattern Alert System - baoquankhu1.vn
FY2029 Earnings Estimate for Genelux Issued By HC Wainwright - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Genelux (NASDAQ:GNLX) Price Target Cut to $20.00 by Analysts at Benchmark - MarketBeat
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside - TipRanks
Genelux Corp 2024 Annual Report: Oncolytic Virus Pipeline, Olvi-Vec Clinical Trials, Strategy, Risks, and Competitive Landscape 66686970719293 - Minichart
Gap Down: Can Genelux Corporation be recession proof2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Genelux (NASDAQ: GNLX) launches $100M at-the-market program with TD Cowen - Stock Titan
Genelux Establishes $100 Million At-The-Market Equity Program - TipRanks
Genelux Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Genelux Establishes $100 Million ATM Equity Program With TD Cowen - TradingView
Genelux (NASDAQ: GNLX) launches $100M at-the-market stock plan - stocktitan.net
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment - Quiver Quantitative
[10-K] GENELUX Corp Files Annual Report | GNLX SEC FilingForm 10-K - Stock Titan
GENELUX 2025 10-K: Revenue $0.01M, Net Loss $32.1M - tradingview.com
Cancer drug readout nears as Genelux says cash lasts into 2027 - Stock Titan
Aug Analyst Calls: What is the long term forecast for Genelux Corporation stockMarket Trend Review & Free Verified High Yield Trade Plans - baoquankhu1.vn
Genelux Corp. (GNLX) Gets a Buy from Maxim Group - The Globe and Mail
Genelux Corp expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock - MarketBeat
[144] GENELUX Corp SEC Filing - Stock Titan
GNLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GNLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Genelux Corporation outperform in the next rallyJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Genelux Corporation to Participate in Upcoming Conferences - Yahoo Finance
8.2% Genelux (NASDAQ: GNLX) stake disclosed by holder Aladar Szalay - Stock Titan
Will Genelux Corporation stock continue dividend increasesMarket Activity Report & Safe Capital Growth Tips - mfd.ru
Genelux Updates Corporate Presentation for Investors and Stakeholders - The Globe and Mail
US Stocks Recap: Is Outlook Therapeutics Inc stock good for income investorsM&A Rumor & Safe Capital Growth Plans - baoquankhu1.vn
Genelux appoints Jason Litten as CMO - MSN
Genelux Corp (GNLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):